

LISTADO DE COMUNICACIONES A CONGRESOS 2021

Estudios de promotor GEICAM y colaboraciones con otros promotores, con autores GEICAM

American Society of Clinical Oncology (ASCO)

ESTUDIO	TIPO COMUNICACIÓN	TÍTULO PUBLICACIÓN	AUTORES	REFERENCIA
GEICAM/2013-02 (PEARL)	POSTER DISCUSSION	CCNE1 mRNA and cyclin E1 protein expression as predictive biomarkers for efficacy of palbociclib plus fulvestrant versus capecitabine in the phase III PEARL study	Pascual J, Gil-Gil M, Zielinski J, Hills M, Ruiz-Borrego M, Ciruelos E.M, García-Murillas I, Muñoz M, Bermejo B, Swift C, Margelí M, Antón A, Nissenbaum B, Murillo L, Liu Y, Herranz J, Caballero R, Guerrero-Zotano A, Turner N, Martín M	2021 ASCO Annual Meeting. June 4-8 2021. Poster discussion session; Breast Cancer-Metastatic. J Clin Oncol 39, 2021 (suppl 15; abstr 1014). DOI: 10.1200/JCO.2021.39.15_s uppl.1014
GEICAM/2013-06 (OlympiA)	ORAL	OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer	Tutt A, Garber J.E, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber R.D, de Azambuja E, Fielding A, Balmana J, Gelmon K.A, Baker N, Arahmani A, Senkus-Konefka E, Mc Fadden E, Karantza V, Lakhani S.R, Yothers G, Campbell C, Geyer C.E	2021 ASCO Annual Meeting. June 4-8 2021. BREAST CANCER—LOCAL/REGIONAL/ADJUVANT DOI: 0.1200/JCO.2021.39.15_s uppl.LBA1 Journal of Clinical Oncology 39, no. 18_suppl

European Society of Medical Oncology (ESMO) Breast Cancer

ESTUDIO	TIPO COMUNICACIÓN	TÍTULO PUBLICACIÓN	AUTORES	REFERENCIA
GEICAM/2014-12 (FLIPPER)	MINI-ORAL	Quality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2-endocrine sensitive advanced breast cancer (ABC): results from GEICAM/2014-12 (FLIPPER) study	Tibau A, Martínez M.T, Ramos M, De La Cruz-Merino L, Santaballa A, O'Connor M, Martínez-Jañez N, Moreno F, Fernández-Pérez I, Virizuela J, Alarcón J, de La Haba-Rodríguez J, Sánchez-Rovira P, C.R Albacar C.R, Bueno C, Kelly C, Casas M, Bezares S, Rosell L, Albanell J	ESMO Breast Cancer Virtual Congress 2021. Mini Oral session 1, 07 May 2021. 94MO. Annals of Oncology (2021) 32 (suppl_2): S60-S78. 10.1016/annonc/annonc508

Congreso del European College of Sport Science (ECSS)

ESTUDIO	TIPO DE COMUNICACIÓN	TÍTULO PUBLICACIÓN	AUTORES	REFERENCIA
GEICAM/2016-02 ELITE	ORAL	Training adaptation in an elite athlete after breast cancer diagnosis. A case report.	Pérez T, Alonso M, San Juan A.F, Antón A, Bezares S, Calvo L, Gil L, Pollán M, Seguí-Palmer M.A, Peinado A.B, Casla S	Abstr.-ID: 411, Presentation format: Oral , Session name: OP-MH03 - Cancer

European Society of Medical Oncology (ESMO)

ESTUDIO	TIPO COMUNICACIÓN	TÍTULO PUBLICACIÓN	AUTORES	REFERENCIA
GEICAM/2013-02 (PEARL)	MINI-ORAL	Overall Survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2-metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs). Final results of the PEARL study	Martín M, Zielinski C, Ruiz-Borrego M, Carrasco E, Ciruelos E.M, Muñoz M, Bermejo B, Margelí M, Csösz T, Antón A, Turner N, Casas M.I, Morales S, Alba E, Calvo L, de la Haba J, Ramos M, Corsaro M, Kahan Z, Gil-Gil M	Annals of Oncology (2021) 32 (suppl_5): S457-S515. 10.1016/annonc/annonc689
GEICAM/2013-03 (PENELOPEB)	MINI-ORAL	Quality of life from the Penelope-B study on high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib	García-Sáenz J.A, Marmé F, Rugo H.S, Untch M, Bonnefoi H, Kim S, Bear H, McCarthy N, Gelmon K, Martin M, Kelly C.M, Reimer T, Toi M, Law E.H, Gnant M, Makris A, Seiler S, Burchardi N, Nekljudova V, Loibl S	Annals of Oncology (2021) 32 (suppl_5): S407-S446. 10.1016/annonc/annonc687
GEICAM/2020-02 COOPERA	ORAL	Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study	Hurvitz S.A, Park Y.H, Bardia A, Quiroga V, López-Valverde V, Steinseifer J, Moore H.M, Spera G, Xue C, Fasching P.A	Mini oral session - Breast cancer, early stage. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. DOI: 10.1016/annonc/annonc741

GEICAM/2015-02 (TEMPO- BREAST)	POSTER	Randomized study of single-agent metronomic versus weekly oral vinorelbine (VNR) as first-line chemotherapy in patients with HR+/HER2- advanced breast cancer	Cazzaniga M.E, Martinez-Jañez N, Kukielka-Budny B, Ulanska M, Bourgeois H, Muñoz Mateu M, Morales S, Bayo J, Cortesi L, Pinter T, Palacova M, Cherciu N, Petru E, Ettl J, De Almeida C, Romain R, Villanova G, Ta Thanh Minh C, Rodrigues A, Frever G	Annals of Oncology (2021) 32 (suppl_5): S447-S456. 10.1016/annonc/annonc688
BIG BREAST METASTASIS TASK FORCE	POSTER	A Global Survey of the Management of Carcinomatous Meningitis (CM) in breast cancer patients	Razis E, Escudero MJ, Palmieri C, Mueller V, Bartsch R, Fumagalli D, Rossi G, Thulin A, Witzel I, Kotecki N, Gil Gil M, Linderholm B, On behalf the Brain Metastasis Task Force (BMTF) of the Breast International Group (BIG)	Annals of Oncology (2021) 32 (suppl_5): S457-S515. 10.1016/annonc/annonc689
GEICAM/2013-03 (PENELOPEB)	POSTER	Health economic properties of palbociclib in breast cancer patients with high risk of relapse following neoadjuvant therapy: Results from the Penelope-B trial	Galactionova K, Loibl S, Salari P, Marmé F, Martin M, Untch M, Bonnefoi H, Kim S, Bear H.D, McCarthy N, Gelmon K, García-Saenz J.A, Kelly C.M, Reimer T, Toi M, Rugo H.S, Gnant M, Makris A, Burchardi N, Schwenkglenks M	Annals of Oncology (2021) 32 (suppl_5): S407-S446. DOI:10.1016/annonc/annonc687

<p>GEICAM/2013-07_TRIO023_EMBRACA</p>	<p>POSTER</p>	<p>Outcomes of patients (pts) who had received prior platinum (PP) therapy in the phase III EMBRACA trial of talazoparib (TALA) vs physician's choice of chemotherapy (PCT) in patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC)</p>	<p>Martin M, Rugo H.S, Hurvitz S.A, Ettl J, Roche H, Lee K-H, Goodwin A, Usari T, Lanzalone S, Guenzel C.A, Blum J, Litton J.K</p>	<p>Annals of Oncology (2021) 32, (suppl_5), S481, SEPTEMBER 01, 2021 . DOI: 10.1016/j.annonc.2021.08.555</p>
<p>GEICAM/2013-07_TRIO023_EMBRACA</p>	<p>POSTER</p>	<p>Talazoparib (TALA) for patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC): Characteristics of patients who experienced hematologic toxicity in the phase III EMBRACA trial</p>	<p>Hurvitz S.A, Rugo H.S, Ettl J, M. Martin M, Roche H, Lee K.H, Goodwin A, Usari T, Lanzalone S, Guenzel C.A, Blum J, Litton J.K</p>	<p>Annals of Oncology (2021) 32, (suppl_5), S482. DOI:10.1016/j.annonc.2021.08.556</p>

Sociedad Española de Oncología Médica (SEOM)

ESTUDIO	TIPO DE COMUNICACIÓN	TÍTULO PUBLICACIÓN	AUTORES	REFERENCIA
GEICAM/2013-02 (PEARL)	ORAL	Gil-Gil J.M, Ruiz-Borrego M, Carrasco E, Ciruelos E.M, Muñoz M, Bermejo B, Margelí M, Martín M, Antón A, Casas M.I, Murillo L , Morales S, Calvo L, Zielinski C, Alba E	Calidad de vida (CV) con Palbociclib (PAL) más terapia Endocrina (TE) versus Capecitabina (CAP) en pacientes con cáncer de mama metastásico (CMM), RH-positivo/HER2-negativo. Resultados de la cohorte Española del estudio PEARL (GEICAM/2013-02)	Congreso Virtual SEOM, 18 al 22 de octubre de 2021. Comunicación Oral en la SESIÓN DE COMUNICACIONES: CÁNCER DE MAMA AVANZADA con el número O-50. JUEVES 21 / OCT 15,30-17,00
GEICAM/2014-03_RegistEM	POSTER DESTACADO	Características de pacientes jóvenes del registro prospectivo de Cáncer de Mama Avanzado (CMA), GEICAM/2014-03 (RegistEM)	López-Tarruella S, Faló C, Álvarez I, Guerrero-Zotano A, Margeli M, Antolin S, Cruz J, Rodríguez C.A, Chacón J.I, Rodríguez-Lescure A, de la Haba J, Tibau A, Mori M, Martinez P, Marín M, Antón A, Miralles J, Bezares S, Rojo F, Jara C	Congreso Virtual SEOM, 18 al 22 de octubre de 2021. Póster destacado número P. DEST-54

San Antonio Breast Cancer Symposium (SABCS)

ESTUDIO	TIPO DE COMUNICACIÓN	TÍTULO PUBLICACIÓN	AUTORES	REFERENCIA
GEICAM/2014-03 (RegistEM)	Spotlight Presentation	Breast cancer clinical subtypes in brain metastases patients from a prospective registry of Advanced Breast Cancer, GEICAM/2014-03 (RegistEM)	López-Tarruella S, Guerrero-Zotano A, Rodríguez C.A, Cruz J, Hernández M, Adrover E, Rodríguez-Lescure A, Falo C, Martínez P, Miguel A, Andrés R, Antolín S, Chacón J. I, Alonso Romero J.L, Villanueva Vázquez R, Ballesteros García A.I, Galán Gramaje M, Malón Jiménez D, Varela Ferreiro S, Moreno Muñoz D, Campo R, Escudero M.J, Bezares S, Rojo F, Álvarez I	2021 San Antonio Breast Cancer Symposium. December 7-10, 2021. Spotlight Session 4, Wednesday, December 8, 2021: 5:00 pm – 6:30 pm CT. Program Number: PD4-08
GEICAM/2014-03 (RegistEM)	POSTER	Features of HER2+ metastatic patients (pts) from a prospective registry of Advanced Breast Cancer (ABC), GEICAM/2014-03 (RegistEM)	Álvarez I, Guerrero-Zotano A, Cruz J, Martínez P, Hernández M, Rodríguez C.A, Rodríguez-Lescure A, Antolín S, Adrover E, Andrés R, Falo C, Chacón J.I, Miguel A, Servitja S, Galán Gramaje M, Margelí Vila M, Gómez Raposo C, Echarri M.J, Villanueva R, Tibau Martorell A, Varela Ferreiro S, Campo R, Miralles J.J, Bezares S, Rojo F, López-Tarruella S.	2021 San Antonio Breast Cancer Symposium. December 7-10, 2021. Poster session 1, Wednesday, December 8, 2021: 7:00 am – 8:30 am CT. Program number: P1-15-04

ESTUDIO	TIPO DE COMUNICACIÓN	TÍTULO PUBLICACIÓN	AUTORES	REFERENCIA
GEICAM/2011-03 (RXPONDER) - GEICAM/2012-01	ORAL	Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG S1007 (RxPONDER)	Kalinsky KM, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LA, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delalogue S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga J-Y, Bermejo B, Ramos-Vasquez M, Jung KH, Ferrero J-M, Schott A, Shak S, Sharma P, Lew D, Miao J, Tripathy D, Puztai L, Hortobagyi G	2021 San Antonio Breast Cancer Symposium. December 7-10, 2021. General Session 2 , Wednesday, December 8, 2021. Program Number:GS2-07
GEICAM/2013-03 (PENELOPEB)	POSTER	Germline BRCA1/2 and other predisposition genes in high-risk early-stage HR+/HER2-breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study	Loibl S, Hauke J, Gelmon K, Marmé F, Ernst C, Martin M, Untch M, Bonnefoi H, Knudsen E, Seock-Ah Im, Angela DeMichele A, Van't Veer L, Kim S-B, Bear H, McCarthy N, Turner N, Witkiewicz A, Rojo F, Fasching P.A, García-Sáenz JA, M. Kelly C, Reimer T, Toi M, Rugo H S, Denkert C, Gnant M, Makris A, Liu Y, Valota O, Felder B, Weber K, Nekljudova V, Hahnen E	2021 San Antonio Breast Cancer Symposium. December 7-10, 2021. Poster Session 5, Friday, December 10, 2021: 7:00 am – 8:30 am CT. Program number: P5-13-36

ESTUDIO	TIPO DE COMUNICACIÓN	TÍTULO PUBLICACIÓN	AUTORES	REFERENCIA
GEICAM/2013-03 (PENELOPEB)	POSTER DISCUSSION	Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib	Denkert C, Marmé F, Martin M Untch M, Bonnefoi H, Sung-Bae Kim, Bear H, Witkiewicz A, Seock-Ah Im, DeMichele A, Van't Veer L, McCarthy N, Stiewe T, Gelmon K, García-Sáenz J, M. Kelly C, Reimer T, Knudsen E, Turner N, Rojo F, Fasching P, Teply-Szymanski J, Liu Y, Toi M, Hope S. Rugo, Gnant M, Makris A, Bärbel Felder, Weber K, Loibl S	2021 San Antonio Breast Cancer Symposium. December 7-10, 2021. Session PD2 - Insights to CDK4/6i resistance: Novel models and clinical/translational genomics
GEICAM/2013-06 (OlympiA)	ORAL	Quality of Life Results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer	Ganz P.A, Bandos H, Spanic T, Friedman S, Müller V, Kümmel S, Delaloge S, Brain E, Toi M, Yamauchi H, Martínez De Dueñas E, Armstrong A, Im S, Song C, Zheng H, Sarosiek T, Sharma P, Rossi G, Rastogi P, Fielding A, Gelber R, Campbell C, Garber J, Geyer C.E, Tutt A, On behalf of the OlympiA Trial Steering Committee and Investigators	2021 San Antonio Breast Cancer Symposium. December 7-10, 2021. GS4-09. Session GS4 - General Session 4
GEICAM/2013-07_TRIO023_EMBRACA	POSTER	Identification of PD-L1+ status as a candidate predictive biomarker of response to talazoparib (TALA) in the phase 3 EMBRACA study	Rugo H.S, Blum J, Laird D, Hurvitz S, Ettl J, Mina L, Lee K-H, Gonçalves A, Yerushalmi R, Young-Hyuck Im, Martin M, Fehrenbacher L, Henri H. Roché, Chen Y, Lanzalone S, Chelliserry J, Eiermann W, Litton W J	2021 San Antonio Breast Cancer Symposium. December 7-10, 2021. P5-13-08. Session P5 - Poster Session 5

ESTUDIO	TIPO DE COMUNICACIÓN	TÍTULO PUBLICACIÓN	AUTORES	REFERENCIA
GEICAM/2014-07 PALLAS	POSTER	Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05)	Naughton M.J, Zahrieh D, Gnant M, Zdenkowski N, Lemieux J, Mao J, Bjelic-Radisic V, Shinn E, Balic M, Thomssen C, Neisel J, Ruiz-Echarri M, Loible S, Claudine Isaacs, Cameron D, Henao Carrasco F, Goetz M, Wette V, Werutsky G, Hope Rugo, Vetter M, Ling-Ming Tseng, Miller K, Fitzal F, Gil-Gil M, Park H, Linderholm B, Bajetta E, Dayao Z, Prat A, Ehrhardt K, Metzger O, Arahmani A, Law E, Partridge A, Carey L, Zoroufy A, Dueck A, Hlauschek D, DeMichele A, Mayer E	2021 San Antonio Breast Cancer Symposium. December 7-10, 2021. P4 - Poster Session 4
GEICAM/2014-07 PALLAS	ORAL	Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial	Gnant M, Dueck A C, Frantal S, Martin M, Burstein H, Greil R, Fox P, Wolff A C, Chan A, Winer E, Singer C, Miller K, Colleoni M, Naughton M, Rubovszky G, Bliss J, Mayer I A, Steger G, Nowecki Z, Hahn O, Wolmark N, Rugo H, Pfeiler G, Fohler H, Metzger O, Schurmans C, P Theall K, R Lu D, Tenner K, Fesl C, DeMichele A, L Mayer E	2021 San Antonio Breast Cancer Symposium. December 7-10, 2021. Session GS1 - General Session 1

ESTUDIO	TIPO DE COMUNICACIÓN	TÍTULO PUBLICACIÓN	AUTORES	REFERENCIA
GEICAM/2014-07 PALLAS	POSTER	Adherence with adjuvant endocrine therapy with or without Palbociclib in the PALLAS trial	Shinn E, Zahrieh D, DeMichele A, Zdenkowski N, Lemieux J, Mao J, Bjelic-Radisic V, Naughton M, Pfeiler G, Gelmon K, Mayer I, Daniel Egle, Zoppoli G, Traina T, Martin M, Antolin S, Haddad T, Chan A, Alistair Ring E, Wolff A, Ponce-Lorenzo J, Dhanusha Sabanathan, Hal Burstein, Zbigniew Ireneusz Nowecki, Gunda Pristauz-Telsnigg, Adam Brufsky, Bellet-Ezquerria M, Theodoros Foukakis, Yelena Novik, Rubovszky G, Muehlbacher K, Metzger O, Theodora Goulioti, Ernest Law, Partridge A, Carey L, Zoroufy A, Hlauschek D, Fesl C Mayer, E Gnant M	2021 San Antonio Breast Cancer Symposium. December 7-10, 2021. Session P4 - Poster Session 4
GEICAM/2020-02 COOPERA	POSTER DISCUSSION	Neoadjuvant giredestrant (GDC-9545) + palbociclib versus anastrozole + palbociclib in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer: Primary analysis of the randomized, open-label, phase II coopERA breast cancer study	Hurvitz S. A, Quiroga V, Park Y.H, Bardia A, López-Valverde V, Steinseifer J, Fernando T.M, Spera G, Xue C and Fasching P.A	2021 San Antonio Breast Cancer Symposium. December 7-10, 2021. Session PD13 - Novel therapeutic approaches in HER2 negative breast cancer

<p>GEICAM/2020-04 SASCIA</p>	<p>POSTER</p>	<p>Phase III postneoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA</p>	<p>Marmé F, Schmidt M, Furlanetto J, Denkert C, Goncalves A, Stickeler E, Reinisch M, Antolín S, Reimer T, Janni W, Aftimos P, Untch M, Michel L, Balic M, Sinn B, Möbus V, Morris P, Schöllhorn L, Schmatloch S, Rey J, Loibl S</p>	<p>2021 San Antonio Breast Cancer Symposium. December 7-10, 2021. OT1. Ongoing Trials Poster Session 1. OT1-02-01</p>
---	---------------	---	--	---